BRD4 and Cancer: going beyond transcriptional regulation
Abstract BRD4, member of the Bromodomain and Extraterminal (BET) protein family, is largely acknowledged in cancer for its role in super-enhancers (SEs) organization and oncogenes expression regulation. Inhibition of BRD4 shortcuts the communication between SEs and target promoters with a subsequent...
Main Authors: | Benedetta Donati, Eugenia Lorenzini, Alessia Ciarrocchi |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-11-01
|
Series: | Molecular Cancer |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12943-018-0915-9 |
Similar Items
-
BRD4 as a Therapeutic Target in Pulmonary Diseases
by: Xia Guo, et al.
Published: (2023-08-01) -
Caveolin-2 is regulated by BRD4 and contributes to cell growth in pancreatic cancer
by: Feng Jiao, et al.
Published: (2020-02-01) -
Targeting bromodomain and extra-terminal proteins to inhibit neuroblastoma tumorigenesis through regulating MYCN
by: Xiyao Shi, et al.
Published: (2022-09-01) -
Design, synthesis, and evaluation of 4-(3-(3,5-dimethylisoxazol-4-yl)benzyl)phthalazin-1(2H)-one derivatives: potent BRD4 inhibitors with anti-breast cancer activity
by: Yingpeng Li, et al.
Published: (2023-11-01) -
Post-Translational Modifications of BRD4: Therapeutic Targets for Tumor
by: Na Liu, et al.
Published: (2022-03-01)